ClinicalTrials.Veeva

Menu
U

Universidade Estadual de Campinas | Faculdade de Ciencias Medicas - Centro de Pesquisa Clinica

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Eplontersen
ION-682884
Diacerein
Metformin
LP352
Dexamethasone
Daratumumab
Daxdilimab
TAR-210
Tenofovir Disoproxil Fumarate

Parent organization

This site is a part of Universidade Estadual de Campinas

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 27 total trials

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of L...

Active, not recruiting
Dravet Syndrome
Drug: Placebo
Drug: LP352

The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Cusatuzumab
Drug: Azacitidine

Acute ischemic stroke (AIS) is a medical emergency that happens because of a sudden stop of blood flow to a part of the brain. This happens when a bl...

Enrolling
Acute Ischemic Stroke
Other: Placebo
Biological: TAK-755

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Active, not recruiting
Bladder Cancer
Biological: Cetrelimab
Drug: TAR-200

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.

Enrolling
Generalized Myasthenia Gravis
Drug: Placebo
Biological: Telitacicept

The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with hereditary transthyreti...

Active, not recruiting
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Drug: Eplontersen

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's ch...

Enrolling
Non-Muscle Invasive Bladder Neoplasms
Drug: Gemcitabine
Combination Product: TAR-210

This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of...

Active, not recruiting
Developmental and Epileptic Encephalopathy
Drug: Placebo
Drug: LP352

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Ionis Pharmaceuticals logo
U
F
L
Takeda logo
A
Amgen logo
Gilead Sciences logo
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems